What this medicine is commonly used for
Procurement teams reference Lecanemab when aligning formulary decisions, documenting a named patient request, or preparing a quotation for a destination country where the product is not routinely stocked.
Informational only. Treatment decisions belong to qualified clinicians and to local labeling.
Shortage and sourcing context
Availability is shaped by staged national launches rather than by manufacturing volume: authorization status differs sharply between jurisdictions, and infusion capacity plus MRI monitoring requirements limit which sites can take delivery. Cold chain is mandatory.
How it is presented
Examples of presentations referenced for this medicine. Actual market presentations vary by country and registration, so check the pack in front of you.
- Concentrate for solution for infusion
Who typically asks us about this medicine
- Patients and families who cannot fill a prescription locally
- Hospital pharmacies managing formulary access during a shortage
- Clinics with defined treatment pathways and continuity of care
- Procurement teams coordinating licensed cross-border sourcing
Full reference text(expand)
Lecanemab (Leqembi): An anti-amyloid monoclonal antibody used in early Alzheimer's disease, given by intravenous infusion in a monitored setting. Procurement-oriented reference for licensed buyers - not medical advice, and availability depends on region and authorization.
Procurement context
Procurement teams reference Lecanemab when aligning formulary decisions, documenting a named patient request, or preparing a quotation for a destination country where the product is not routinely stocked.
What makes it hard to source
Availability is shaped by staged national launches rather than by manufacturing volume: authorization status differs sharply between jurisdictions, and infusion capacity plus MRI monitoring requirements limit which sites can take delivery. Cold chain is mandatory.